Cascade Chemistry selected to help speed clinical testing of promising investigational drug for COVID-19

Cascade Chemistry selected to help speed clinical testing of promising investigational drug for COVID-19

Cascade Chemistry selected to help speed clinical testing of promising investigational drug for COVID-19

Cascade Chemistry, a leading contract research and manufacturing organization serving the pharmaceutical, materials, and chemical industries, today announced that it has been selected to produce the active pharmaceutical ingredient for clinical trial supplies of RBT-9, an investigational therapy entering a Phase 2 trial for the treatment of COVID-19 patients who are at high risk of deteriorating health due to age or comorbid conditions such as kidney or cardiovascular disease.